The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|July 2, 2014
- Pharmaceutical Technology-07-02-2014
- Volume 38
- Issue 7
Laboratory Filter-Dryer Enables Scalability
Author(s)Melanie Sena
Laboratory Filter-Dryer Enables Scalability
The GFD laboratory nutsche filter–dryer from Powder Systems Limited, originally developed in glass, is available in metal to allow higher pressures. The laboratory- scale unit can be used for feasibility studies and trials before scaling up to a commercial-scale agitated nutsche filter dryer (ANFD). The stainless-steel 316 L or alloy C22 versions allow better replication of the pressures in commercial ANFD. The Mini Lab GFD unit has a total volume of 0.3 L that can filter a cake volume up to 0.1 L and is suitable for laboratory-scale trials. The Lab GFD size includes a removable filtration basket of 0.01-m² for a cake volume of 0.5 L for small-scale synthesis. The Maxi Lab GFD filters a cake volume of 5 L with 0.05-m² filtration area.
Articles in this issue
over 12 years ago
Trends in Manufacturing and Equipmentover 12 years ago
The Mainstreaming of Continuous Flow API Synthesisover 12 years ago
Health Systems Raise the Bar on Reimbursing New Drugsover 12 years ago
Data Integrityover 12 years ago
Environmental Monitoring System Improves Efficiencyover 12 years ago
Automating Online Sampling of Bioprocessesover 12 years ago
Sieve Shakers Ensure Reliabilityover 12 years ago
Sterilization of Blow-Fill-Seal Equipment for Aseptic FillingRelated to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.